Balyasny Asset Management LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 55.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,330 shares of the company’s stock after purchasing an additional 15,830 shares during the period. Balyasny Asset Management LLC’s holdings in Zoetis were worth $2,765,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. CGOV Asset Management raised its holdings in shares of Zoetis by 2.7% during the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after purchasing an additional 4,405 shares during the period. First Interstate Bank raised its holdings in shares of Zoetis by 3.5% during the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after purchasing an additional 76 shares during the period. Investment House LLC raised its holdings in shares of Zoetis by 385.1% during the first quarter. Investment House LLC now owns 41,235 shares of the company’s stock valued at $2,201,000 after purchasing an additional 32,735 shares during the period. Findlay Park Partners LLP raised its holdings in shares of Zoetis by 15.2% during the first quarter. Findlay Park Partners LLP now owns 2,676,247 shares of the company’s stock valued at $142,831,000 after purchasing an additional 352,262 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Zoetis by 2.3% during the first quarter. Van ECK Associates Corp now owns 1,278,522 shares of the company’s stock valued at $68,235,000 after purchasing an additional 28,706 shares during the period. Hedge funds and other institutional investors own 93.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Balyasny Asset Management LLC Increases Stake in Zoetis Inc. (ZTS)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/10/12/balyasny-asset-management-llc-increases-stake-in-zoetis-inc-zts.html.
Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Tuesday, September 26th. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, Hilliard Lyons assumed coverage on shares of Zoetis in a report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $65.44.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 64.28 on Thursday. The firm has a 50-day moving average of $63.65 and a 200 day moving average of $60.76. The stock has a market cap of $31.44 billion, a price-to-earnings ratio of 36.34 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $65.83.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the previous year, the firm posted $0.49 earnings per share. Zoetis’s quarterly revenue was up 5.0% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post $2.34 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be issued a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.65%. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.